This article first appeared on GuruFocus .
An In-Depth Look at the Upcoming Payout and Long-Term Dividend Sustainability
Hansoh Pharmaceutical Group Co Ltd ( HNSPF ) recently announced a total dividend of $0.04 per share, with the ex-dividend date set for 2026-09-22. This distribution consists of a $0.04 per share cash dividend payable on 2026-10-29. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using data from GuruFocus, let's look into Hansoh Pharmaceutical Group Co Ltd's dividend performance and assess its sustainability. For value investors, understanding whether this payout is a one-time event or part of a durable capital return policy is essential before making any portfolio decisions.
What Does Hansoh Pharmaceutical Group Co Ltd Do?
-
This Powerful Chart Made Peter Lynch 29% A Year For 13 Years
-
How to calculate the intrinsic value of a stock?
-
Is HNSPF fairly valued? Test your thesis with our free DCF calculator.
Hansoh Pharmaceutical Group is a Chinese pharmaceutical company engaged in the research, development, production, and commercialization of drugs, primarily in the People's Republic of China. Its portfolio spans therapeutic areas including oncology, anti-infectives, central nervous system disorders, metabolic diseases, and immunology, with products sold in both branded and generic forms. The company markets its medicines to hospitals, medical institutions, and pharmacies across mainland China, which accounts for the vast majority of its revenue. Hansoh generates income mainly through the sale of pharmaceutical products, supplemented by licensing and collaboration arrangements with domestic and international partners. It operates research and development centers and manufacturing facilities in China and has expanded its pipeline through in-licensing deals and partnerships with global biopharmaceutical firms. The company is listed on the Hong Kong Stock Exchange.
A Glimpse at Hansoh Pharmaceutical Group Co Ltd's Dividend History
Hansoh Pharmaceutical Group Co Ltd has maintained a consistent dividend payment record since 2021. Dividends are currently distributed on a bi-annually basis, meaning shareholders receive two payments per year rather than a single annual distribution. This semi-annual cadence can be attractive to income-focused investors because it provides more frequent cash flow and allows the company to adjust payouts in response to changing business conditions. Below is a chart showing annual Dividends Per Share for tracking historical trends, which helps investors visualize whether the payout has been stable, rising, or volatile over time.
Breaking Down Hansoh Pharmaceutical Group Co Ltd's Dividend Yield and Growth
As of today, Hansoh Pharmaceutical Group Co Ltd currently has a 12-month trailing dividend yield of 1.30% and a 12-month forward dividend yield of 1.46%. The trailing yield reflects dividends actually paid over the past year, while the forward yield estimates future payments based on the latest declared distribution. The gap between the two suggests an expectation of increased dividend payments over the next 12 months, a signal that management may be growing more confident about cash generation. For investors comparing income opportunities, a rising forward yield relative to the trailing figure is generally viewed as a positive indicator of shareholder-friendly capital allocation.
Over the past three years, Hansoh Pharmaceutical Group Co Ltd's annual dividend growth rate was 39.40%. That is a remarkably strong pace, though investors should recognize that high growth rates often reflect a small base or a period of catch-up rather than a rate that can be sustained indefinitely. Based on Hansoh Pharmaceutical Group Co Ltd's dividend yield and five-year growth rate, the 5-year yield on cost of Hansoh Pharmaceutical Group Co Ltd stock as of today is approximately 1.30%. Yield on cost measures the annual dividend return relative to an investor's original purchase price, making it a useful gauge of long-term income compounding.
The Sustainability Question: Payout Ratio and Profitability
To assess the sustainability of the dividend, one needs to evaluate the company's payout ratio. The dividend payout ratio provides insights into the portion of earnings the company distributes as dividends. A lower ratio suggests that the company retains a significant part of its earnings, thereby ensuring the availability of funds for future growth and unexpected downturns. As of 2026-06-30, Hansoh Pharmaceutical Group Co Ltd's dividend payout ratio is 0.36, meaning roughly 36% of earnings are paid out to shareholders. That leaves a substantial cushion for reinvestment in research and development, debt reduction, or future dividend increases, which is a favorable trait for a pharmaceutical company operating in a capital-intensive industry.
Hansoh Pharmaceutical Group Co Ltd's profitability rank offers an understanding of the company's earnings prowess relative to its peers. GuruFocus ranks Hansoh Pharmaceutical Group Co Ltd's profitability 9 out of 10 as of 2026-06-30, suggesting good profitability prospects. The company has reported positive net income for each year over the past decade, further solidifying its high profitability. A decade-long record of positive earnings demonstrates resilience across economic cycles and provides a dependable foundation from which dividends can be funded without straining the balance sheet.
Growth Metrics: The Future Outlook
To ensure the sustainability of dividends, a company must have robust growth metrics. Hansoh Pharmaceutical Group Co Ltd's growth rank of 9 out of 10 suggests that the company's growth trajectory is good relative to its competitors. Revenue is the lifeblood of any company, and Hansoh Pharmaceutical Group Co Ltd's revenue per share , combined with the 3-year revenue growth rate , indicates a strong revenue model. Hansoh Pharmaceutical Group Co Ltd's revenue has increased by approximately 16.30% per year on average, a rate that outperforms approximately 82.76% of global competitors. Expanding revenue gives management more flexibility to raise dividends over time.
The company's 3-year EPS growth rate showcases its capability to grow its earnings, a critical component for sustaining dividends in the long run. During the past three years, Hansoh Pharmaceutical Group Co Ltd's earnings increased by approximately 29.10% per year on average, a rate that outperforms approximately 75.16% of global competitors. Lastly, the company's 5-year EBITDA growth rate of 14.70%, which outperforms approximately 64.66% of global competitors, further confirms that operating cash flow is expanding. Together, these metrics paint a picture of a business whose dividend is supported by genuine fundamental momentum rather than accounting maneuvers.
Next Steps
Hansoh Pharmaceutical Group Co Ltd's upcoming $0.04 per share dividend, payable on 2026-10-29 with an ex-dividend date of 2026-09-22, is backed by a compelling set of fundamentals. A payout ratio of 0.36, a profitability rank of 9 out of 10, a growth rank of 9 out of 10, and double-digit growth in revenue, earnings, and EBITDA all point to a dividend that appears well covered and capable of further increases. The 39.40% three-year dividend growth rate is striking, though prudent investors should watch whether such momentum moderates as the payout base grows. For value investors, the key question is whether Hansoh's pipeline and partnership strategy can keep earnings compounding fast enough to justify continued double-digit dividend raises. Monitoring the next interim report and any changes to the payout ratio will help answer that question.
GuruFocus Premium users can screen for high-dividend yield stocks using the High Dividend Yield Screener .
